The rationale and use of hypomethylation agents in adult acute myeloid leukemia

Author： Thomas Xavier   Chelghoum Youcef   Barraco Fiorenza   Troncy Jacques  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.4, Iss.2, 2009-02, pp. : 195-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epigenetics and Adult Acute Myeloid Leukemia

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 13, Iss. 2, 2015-08 ,pp. : 117-133

Bentham Science Publishers

Access to resources Recommend Favorite

New agents for acute myeloid leukemia: is it time for targeted therapies?

By Ferrara Felicetto  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 2, 2012-02 ,pp. : 179-189

Informa Healthcare

Access to resources Recommend Favorite

The graceful exit or reluctant demise of the older adult with acute myeloid leukemia

By  

Cancer, Vol. 121, Iss. 16, 2015-08 ,pp. : 2678-2680

Blackwell Publishing

Access to resources Recommend Favorite

Acute Myeloid Leukemia

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 962-962

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Pharmacogenomics in acute myeloid leukemia

By Roumier Christophe   Cheok Meyling H  

Pharmacogenomics, Vol. 10, Iss. 11, 2009-11 ,pp. : 1839-1851

Future Medicine

Access to resources Recommend Favorite